Tasigna — CareFirst (Caremark)

Initial criteria

• Treatment as a single agent for residual, unresectable, tumor rupture, recurrent/progressive, or metastatic disease
• Member has failed at least four FDA-approved therapies (e.g., imatinib, sunitinib, regorafenib, ripretinib)

Reauthorization criteria

• No evidence of unacceptable toxicity while on the current regimen

Approval duration

Initial and continuation 12 months